Revelation Biosciences, Inc.
REVB
$1.24
-$0.02-1.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.73% | 47.61% | 46.78% | -60.79% | -12,400.83% |
| Total Depreciation and Amortization | -2.87% | 5.19% | 10.34% | 14.29% | 10.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 453.78% | 4,654.69% | 506.11% | 176.02% | 101.38% |
| Change in Net Operating Assets | 99.83% | -106.07% | -238.86% | -584.04% | -448.56% |
| Cash from Operations | 54.86% | 39.37% | -96.08% | -113.80% | -151.45% |
| Capital Expenditure | -- | 147.97% | 100.00% | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 147.97% | 100.00% | 100.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -2.61% | 76.86% | 99.72% | 37.17% | -8.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.93% | 76.86% | 99.72% | 37.17% | -8.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 176.49% | 182.75% | -89.63% | -244.23% | -181.51% |